Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol as an MRI Contrast Agent for Inflammation in Multiple Sclerosis
NCT02511028Phase 1Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Nov 2015
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferumoxytol in multiple sclerosis (MS), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Change in gradient-echo T2*-weighted signal in the globus pallidus at 6 months. Started Nov 2015; status: completed.
02
Drugs
ferumoxytol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02511028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511028.